Chapter 3: Pharmacodynamics — Module 4: Signal Transduction, Receptor Superfamilies and Downstream Pharmacodynamics
1. Which G protein alpha subunit class is coupled to the mu-opioid receptor, and what is the primary second-messenger consequence of mu-opioid receptor activation?
A) G-alpha-i -- adenylyl cyclase is inhibited, reducing intracellular cAMP (cyclic adenosine monophosphate); reduced PKA (protein kinase A) activity leads to decreased phosphorylation of voltage-gated calcium channels and GIRK (G protein-coupled inwardly rectifying potassium) channels open, hyperpolarizing the neuron and reducing neuronal excitability -- this is the primary signaling mechanism underlying opioid analgesia, sedation, and euphoria
B) G-alpha-s -- adenylyl cyclase stimulation -- elevated cAMP -- PKA activation -- increased calcium channel opening and enhanced neurotransmitter release -- producing excitatory rather than inhibitory neuronal effects
C) G-alpha-q -- phospholipase C-beta activation -- IP3 (inositol trisphosphate) and DAG (diacylglycerol) generation -- intracellular calcium release and PKC (protein kinase C) activation -- producing smooth muscle contraction rather than neuronal inhibition
D) G-alpha-12/13 -- RhoGEF activation -- Rho/ROCK (Rho-associated coiled-coil kinase) signaling -- cytoskeletal rearrangement rather than ion channel modulation or cAMP changes
E) G-alpha-s -- adenylyl cyclase stimulation -- elevated cAMP -- EPAC (exchange protein directly activated by cAMP) activation -- enhanced synaptic vesicle priming and increased neurotransmitter release
ANSWER: A
Rationale:
The mu-opioid receptor is a prototypical Gi/Go-coupled GPCR. Upon agonist binding, Gi alpha subunits directly inhibit adenylyl cyclase, reducing intracellular cAMP. Reduced cAMP decreases PKA activity, leading to reduced phosphorylation of voltage-gated calcium channels. Simultaneously, freed Gbetagamma subunits directly activate GIRK channels, increasing potassium conductance and hyperpolarizing the cell membrane. Together these effects reduce neuronal excitability -- decreasing action potential probability, reducing neurotransmitter release at presynaptic terminals, and inhibiting postsynaptic activation. These Gi-mediated mechanisms produce analgesia, sedation, euphoria, and respiratory depression. Chronic opioid exposure produces compensatory upregulation of adenylyl cyclase (adenylyl cyclase supersensitization), contributing to physical dependence and withdrawal hyperactivity.
Option B: Option B is incorrect -- Gs-coupled receptors stimulate adenylyl cyclase and increase cAMP; beta-adrenergic receptors are the classic example; mu-opioid receptors are Gi, not Gs.
Option C: Option C is incorrect -- Gq-coupled receptors activate phospholipase C-beta; alpha1-adrenergic and M1/M3 muscarinic receptors are classic examples; mu-opioid receptors do not couple to Gq as their primary transducer.
Option D: Option D is incorrect -- G-alpha-12/13 couples to RhoGEF and drives cytoskeletal changes; thromboxane A2 receptors are classic examples; this is not the mu-opioid receptor mechanism.
Option E: Option E is incorrect -- EPAC is an effector of elevated cAMP relevant to Gs-coupled signaling; mu-opioid receptors reduce cAMP rather than increase it.
2. The beta1-adrenergic receptor couples to which G protein, and what is the chronotropic consequence of beta1 activation in the sinoatrial node?
B) G-alpha-q -- phospholipase C-beta activated -- IP3-mediated SR (sarcoplasmic reticulum) calcium release -- increased intracellular calcium -- positive inotropy rather than primary chronotropy
C) G-alpha-12/13 -- Rho kinase activation -- increased myosin light chain phosphorylation in the SA node -- reduced heart rate through physical compression of pacemaker tissue
D) G-alpha-s -- adenylyl cyclase stimulated -- elevated cAMP -- direct cAMP binding to GIRK channels causing their closure -- membrane depolarization -- positive chronotropy through reduced potassium conductance
E) G-alpha-s -- adenylyl cyclase stimulated -- increased cAMP -- PKA-mediated phosphorylation and enhanced activation of HCN4 (the primary cardiac If channel) in the sinoatrial node -- accelerated spontaneous diastolic depolarization -- positive chronotropy (increased heart rate)
ANSWER: E
Rationale:
The beta1-adrenergic receptor is coupled to Gs. Agonist binding activates Gs-alpha, which stimulates adenylyl cyclase to produce cAMP. Elevated cAMP directly activates HCN4 -- the primary isoform of the hyperpolarization-activated cyclic nucleotide-gated channel responsible for the funny current (If) in the sinoatrial node. HCN4 is directly gated by cAMP binding to its cytoplasmic C-terminal domain -- cAMP shifts the voltage-activation curve rightward, increasing the rate of If activation during diastole. Additionally, PKA phosphorylates L-type calcium channels (Cav1.2), increasing calcium influx and further accelerating spontaneous depolarization. The combined effect is faster spontaneous diastolic depolarization and increased heart rate -- positive chronotropy. This mechanism is the target of beta-blockers and is exploited by catecholamines requiring heart rate support.
Option A: Option A is incorrect -- Gi-coupled receptors reduce cAMP and slow the heart; M2 muscarinic receptors use this mechanism; beta1 receptors are Gs, not Gi.
Option B: Option B is incorrect -- Gq activation and IP3-mediated calcium release is the mechanism of alpha1-adrenergic and M1/M3 muscarinic receptors; beta1 receptors do not couple to Gq as their primary transducer.
Option C: Option C is incorrect -- G-alpha-12/13/Rho kinase signaling is not the mechanism of beta1-mediated chronotropy.
Option D: Option D is incorrect -- while cAMP does influence GIRK channels, the primary chronotropic mechanism is HCN4 stimulation via direct cAMP binding and PKA-mediated calcium channel phosphorylation.
3. At the GABA-A receptor, benzodiazepines act as positive allosteric modulators (PAMs). Which of the following correctly describes their binding site and mechanism?
A) Benzodiazepines bind the transmembrane domain of the GABA-A receptor and increase the duration of each individual channel opening event, similar to barbiturates but through a different binding site
B) Benzodiazepines bind the orthosteric GABA binding site and act as partial agonists, producing submaximal chloride conductance even at saturating concentrations
C) Benzodiazepines act at the neurosteroid binding site on the GABA-A receptor, increasing the probability of channel opening through a mechanism identical to endogenous neurosteroids such as allopregnanolone
D) Benzodiazepines bind the alpha/gamma subunit interface of the GABA-A receptor at a site distinct from the GABA binding site; they do not directly open chloride channels but increase the frequency of channel opening events in response to GABA -- they have no effect in the absence of GABA; this GABA-dependence and frequency (not duration) enhancement distinguishes them from barbiturates and explains their wider safety margin
E) Benzodiazepines bind extracellularly to the GABA-A receptor and allosterically increase GABA binding affinity for the orthosteric site, producing a leftward shift in the GABA concentration-response curve without altering channel kinetics
ANSWER: D
Rationale:
Benzodiazepines bind to a specific allosteric site at the interface between the alpha and gamma subunits of the GABA-A receptor -- distinct from the orthosteric GABA binding site at the alpha/beta subunit interface. This site requires specific alpha subunit isoforms (alpha1, alpha2, alpha3, or alpha5 -- but not alpha4 or alpha6) and the gamma2 subunit for benzodiazepine sensitivity. Critically, benzodiazepines require GABA to be present -- they cannot directly open the chloride channel in the absence of GABA. Their mechanism is to increase the frequency of chloride channel opening events per unit time in response to GABA, without altering the duration of individual opening events. This frequency enhancement is the mechanistic distinction from barbiturates (which increase channel opening duration). The GABA-requirement and frequency-only enhancement explain the superior safety margin of benzodiazepines: they can only potentiate existing GABA activity and cannot open channels independently, providing a ceiling to CNS depression at the level of available GABA.
Option A: Option A is incorrect -- increasing duration of channel opening is the mechanism of barbiturates, not benzodiazepines.
Option B: Option B is incorrect -- benzodiazepines do not bind the orthosteric GABA site and are not partial agonists; they bind the alpha/gamma interface as positive allosteric modulators.
Option C: Option C is incorrect -- neurosteroids bind transmembrane sites distinct from the benzodiazepine site.
Option E: Option E is incorrect -- while benzodiazepines do increase GABA apparent affinity, the primary mechanism is frequency enhancement of channel opening.
4. Succinylcholine produces neuromuscular blockade through which mechanism at the nicotinic acetylcholine receptor (nAChR)?
A) Competitive reversible antagonism -- it occupies both ACh binding sites simultaneously and prevents ACh-mediated channel opening; reversal occurs spontaneously as succinylcholine plasma concentrations fall
B) Depolarizing blockade -- it acts as a nicotinic receptor agonist, causing initial channel opening and end-plate depolarization (visible as muscle fasciculations), followed by sustained end-plate depolarization that keeps the nicotinic receptor in the desensitized state; in the desensitized state the receptor cannot respond to ACh and neuromuscular blockade ensues; the duration is determined by plasma cholinesterase hydrolysis of succinylcholine, typically 5-10 minutes
C) Allosteric inhibition -- it binds the delta subunit interface and locks the channel in the closed resting state without causing depolarization or fasciculations, producing a block pharmacologically identical to non-depolarizing agents
D) Non-competitive channel block -- it enters the open nicotinic channel and physically blocks ion flow without occupying the ACh binding site, producing blockade only after initial channel opening by endogenous ACh
E) Inverse agonism -- it stabilizes the desensitized conformation of the nicotinic receptor before any channel opening occurs, producing blockade without the initial fasciculation phase seen with agonist-induced depolarization
ANSWER: B
Rationale:
Succinylcholine is a depolarizing neuromuscular blocking agent -- a structural analogue of acetylcholine that acts as a nicotinic receptor agonist at the neuromuscular junction. It binds both alpha subunit ACh binding sites and activates the channel, producing initial end-plate depolarization manifest as muscle fasciculations. Unlike ACh (rapidly hydrolyzed by AChE), succinylcholine is slowly hydrolyzed by plasma cholinesterase (pseudocholinesterase/butyrylcholinesterase). The sustained depolarization produces Phase I block -- the nicotinic receptor transitions to the desensitized state (unable to respond to agonist), producing flaccid paralysis. Duration is typically 5-10 minutes in patients with normal plasma cholinesterase, making it the agent of choice for rapid sequence intubation when short duration is required. With prolonged or high-dose exposure, Phase II block can develop with characteristics resembling non-depolarizing blockade.
Option A: Option A is incorrect -- competitive reversible antagonism is the mechanism of non-depolarizing agents such as rocuronium; succinylcholine is an agonist, not an antagonist.
Option C: Option C is incorrect -- succinylcholine causes visible fasciculations before paralysis, demonstrating agonist-induced channel opening precedes blockade; allosteric inhibition without depolarization does not explain the clinical picture.
Option D: Option D is incorrect -- non-competitive channel block is the mechanism of drugs such as memantine at NMDA receptors; succinylcholine acts at the orthosteric ACh binding site as an agonist.
Option E: Option E is incorrect -- succinylcholine causes initial muscle activation (fasciculations), not silent receptor inactivation without depolarization.
5. The NMDA receptor has two requirements for channel opening beyond ligand binding that are unique among ionotropic glutamate receptors. Which of the following correctly identifies both requirements?
A) Simultaneous binding of glutamate at both GluN2 subunits is required, plus membrane hyperpolarization to remove Mg2+ block -- making NMDA receptors maximally active at resting membrane potential
B) Dual glycine binding at both GluN1 and GluN2 subunits simultaneously, plus synaptic GABA release to provide the co-agonist inhibitory current needed for channel gating
C) Sequential binding of glutamate followed by GABA at two separate binding sites, plus any membrane depolarization above -80 mV to relieve channel block
D) Simultaneous binding of glutamate at the GluN1 subunit AND AMPA receptor co-activation at an adjacent synapse to provide the depolarizing current needed to relieve Mg2+ block
E) Simultaneous binding of glutamate at the GluN2 subunit AND glycine (or D-serine) at the GluN1 subunit as a mandatory co-agonist, plus membrane depolarization sufficient to relieve the voltage-dependent Mg2+ block of the channel pore -- this coincidence detection mechanism makes NMDA receptors molecular switches for synaptic plasticity
ANSWER: E
Rationale:
The NMDA receptor requires three simultaneous conditions for channel opening -- making it a molecular coincidence detector. First, glutamate must bind to the GluN2 subunit. Second, glycine (or D-serine in some synapses) must bind to the GluN1 subunit as a mandatory co-agonist -- the receptor cannot open without both ligands present, regardless of membrane potential. Third, the cell membrane must be sufficiently depolarized to relieve the voltage-dependent Mg2+ block of the channel pore. At resting membrane potential (approximately -70 mV), Mg2+ ions lodge in the channel pore and block ion flow even when both ligands are bound. Depolarization (typically by prior AMPA receptor activation) expels the Mg2+ block, allowing the channel to open and conduct calcium, sodium, and potassium. The calcium influx is the critical signal for long-term potentiation and synaptic plasticity. The coincidence detection property -- requiring both presynaptic glutamate release AND postsynaptic depolarization -- makes NMDA receptors the molecular substrate for Hebbian learning.
Option A: Option A is incorrect -- membrane depolarization (not hyperpolarization) relieves Mg2+ block; additionally, glycine at GluN1 is required.
Option B: Option B is incorrect -- glycine binds GluN1, not GluN2; GABA is not a co-agonist at NMDA receptors.
Option C: Option C is incorrect -- GABA is not a ligand at NMDA receptors; glutamate and glycine are the required ligands.
Option D: Option D is incorrect -- glutamate binds GluN2, not GluN1; AMPA receptor co-activation is one source of depolarization but not an absolute requirement.
6. Ketamine produces analgesia and anesthesia through which mechanism at the NMDA receptor?
A) Competitive antagonism at the glutamate binding site on the GluN2 subunit -- ketamine binds the same site as glutamate and prevents its access, blocking NMDA activation without requiring prior channel opening
B) Selective blockade of GluN2B-containing NMDA receptor subtypes only -- ketamine binds only GluN2B-containing receptors, explaining selective dissociative and analgesic effects without blocking all NMDA populations
C) Use-dependent open-channel block -- ketamine enters and physically blocks the NMDA receptor channel pore only when the channel is in the open state (requiring prior glutamate + glycine binding AND membrane depolarization to relieve Mg2+ block); this use-dependence means channels that are rarely activated are less effectively blocked, explaining ketamine's preferential action at tonically active NMDA receptors involved in pain processing and dissociation
D) Positive allosteric modulation at the glycine co-agonist site -- ketamine enhances glycine binding and increases NMDA channel opening probability, producing dissociation through receptor overactivation
E) Irreversible non-competitive antagonism -- ketamine covalently modifies the Mg2+ binding site in the channel pore, permanently blocking NMDA conduction until new receptor protein is synthesized
ANSWER: C
Rationale:
Ketamine is an uncompetitive (use-dependent open-channel) NMDA receptor antagonist. It cannot block the channel unless the channel is already open -- it must enter the pore through the open gate. For ketamine to access its blocking site in the channel pore, glutamate must be bound at GluN2, glycine must be bound at GluN1, and the membrane must be depolarized enough to relieve Mg2+ block. Only after the channel opens can ketamine enter and block the pore from the inside. The use-dependence has important pharmacodynamic implications: NMDA receptors with low activity are relatively protected from ketamine block, while those with high activity (pain signaling, dissociative circuits) are preferentially blocked. This partially explains ketamine's analgesic properties at sub-anesthetic doses -- dorsal horn NMDA receptors involved in central sensitization are tonically active and thus preferentially blocked. At higher doses, broader NMDA receptor blockade throughout the CNS produces dissociative anesthesia. Esketamine (S-ketamine) is 3-4 times more potent than R-ketamine and is approved for treatment-resistant depression.
Option A: Option A is incorrect -- competitive antagonism at the glutamate site would not require channel opening; ketamine requires the channel to open first.
Option B: Option B is incorrect -- while ketamine has some GluN2B preference, it is not exclusively selective; its primary mechanism is open-channel block at multiple NMDA subtypes.
Option D: Option D is incorrect -- ketamine is an NMDA antagonist, not a PAM; it reduces NMDA receptor function.
Option E: Option E is incorrect -- ketamine block is reversible; it does not covalently modify the channel.
7. GRK-mediated phosphorylation of an agonist-occupied GPCR initiates which sequence of events?
A) Beta-arrestin recruitment to the phosphorylated receptor -- sterically blocking further G protein coupling, targeting the receptor for clathrin-mediated endocytosis through interaction with clathrin and AP2 (adaptor protein 2) adaptor proteins, and serving as a scaffold for G protein-independent (arrestin-biased) signaling through ERK (extracellular signal-regulated kinase) and other kinases
B) Direct G protein dissociation from the receptor -- GRK phosphorylation sterically removes the G protein alpha subunit from its coupling site on the intracellular loops, halting signal transduction without requiring beta-arrestin
C) Receptor dimerization with an unphosphorylated receptor monomer -- the phosphorylated-unphosphorylated dimer forms a stable signaling complex with enhanced G protein coupling duration
D) Activation of phospholipase D at the plasma membrane -- PLD hydrolyzes phosphatidylcholine to generate phosphatidic acid and choline, which serve as second messengers for receptor recycling
E) Immediate receptor gene transcription downregulation -- GRK phosphorylation activates a nuclear signaling cascade that reduces mRNA transcription of the receptor gene, explaining long-term receptor density reduction with chronic agonist exposure
ANSWER: A
Rationale:
GRK-mediated phosphorylation of agonist-occupied GPCRs is the first step in a regulated desensitization and internalization sequence. GRKs phosphorylate specific serine and threonine residues on the receptor's intracellular C-terminal tail and third intracellular loop. Phosphorylation creates a high-affinity docking site for beta-arrestin proteins (beta-arrestin1 and beta-arrestin2). Beta-arrestin binding sterically occludes the receptor's G protein coupling surface (homologous desensitization), recruits clathrin and the AP2 adaptor complex driving receptor clustering into clathrin-coated pits and subsequent endocytosis, and serves as a scaffold for G protein-independent signaling cascades including ERK1/2 -- the basis of biased agonism.
Option B: Option B is incorrect -- GRK phosphorylation does not directly dissociate G proteins; it creates the phosphorylation pattern for beta-arrestin docking, which then blocks G protein re-coupling.
Option C: Option C is incorrect -- GRK-phosphorylated receptor dimerization forming enhanced signaling complexes is not the established desensitization mechanism.
Option D: Option D is incorrect -- phospholipase D activation is not the primary consequence of GRK phosphorylation.
Option E: Option E is incorrect -- GRK phosphorylation does not directly activate nuclear transcription pathways; receptor mRNA downregulation involves distinct regulatory mechanisms.
8. Barbiturates differ critically from benzodiazepines in their mechanism at the GABA-A receptor. Which statement correctly distinguishes barbiturate from benzodiazepine pharmacodynamics?
A) Barbiturates bind the alpha/gamma subunit interface (the benzodiazepine site) at higher concentrations but with lower affinity, producing GABA-A modulation through an identical mechanism with less receptor selectivity
B) Barbiturates act as negative allosteric modulators at the neurosteroid binding site on GABA-A -- at therapeutic doses they reduce GABA-A function to produce paradoxical CNS excitation before achieving sedation
C) Barbiturates bind the orthosteric GABA binding site and act as full GABA agonists -- producing maximum chloride conductance independent of GABA concentrations
D) Barbiturates bind a transmembrane site on the GABA-A receptor and increase the duration of channel opening events at therapeutic concentrations -- unlike benzodiazepines which increase opening frequency; at higher concentrations barbiturates can directly open chloride channels in the absence of GABA, removing the safety ceiling that GABA-dependence provides for benzodiazepines and explaining their far narrower therapeutic index
E) Barbiturates and benzodiazepines bind identical transmembrane sites and act through identical mechanisms -- clinical safety differences reflect pharmacokinetic differences in half-life and tissue distribution rather than pharmacodynamic differences at the receptor
ANSWER: D
Rationale:
Benzodiazepines bind the alpha/gamma subunit interface and increase the frequency of chloride channel opening in response to GABA -- they cannot open the channel without GABA present. Barbiturates bind transmembrane sites on the GABA-A receptor (at the beta subunit transmembrane domains) and increase the duration of individual chloride channel opening events at therapeutic concentrations. At high concentrations, barbiturates can directly open GABA-A chloride channels in the absence of GABA -- removing the GABA-dependence that provides the safety ceiling for benzodiazepines. This direct channel-opening ability explains barbiturate lethality in overdose: there is no ceiling to barbiturate-induced chloride conductance because the drug can function independently of GABA availability. Benzodiazepine overdose alone is rarely fatal because they cannot exceed the ceiling imposed by available GABA.
Option A: Option A is incorrect -- barbiturates do not bind the benzodiazepine (alpha/gamma) site; they bind transmembrane sites with a fundamentally different mechanism.
Option B: Option B is incorrect -- barbiturates are positive, not negative, allosteric modulators of GABA-A.
Option C: Option C is incorrect -- barbiturates bind transmembrane sites and work allosterically, not at the orthosteric GABA site.
Option E: Option E is incorrect -- the pharmacodynamic differences at the receptor level are fundamental and clinically critical, not reducible to pharmacokinetics.
9. The alpha1-adrenergic receptor signals through which G protein and produces vascular smooth muscle contraction through which intracellular mechanism?
A) G-alpha-s -- adenylyl cyclase stimulation -- elevated cAMP -- PKA phosphorylation of myosin light chain kinase (MLCK) -- MLCK inactivation -- reduced myosin phosphorylation -- smooth muscle relaxation rather than contraction
The alpha1-adrenergic receptor is a classic Gq-coupled GPCR. When norepinephrine or epinephrine binds the alpha1 receptor, Gq-alpha activates phospholipase C-beta (PLC-beta). PLC-beta cleaves PIP2 (phosphatidylinositol-4,5-bisphosphate) into IP3 and DAG. IP3 binds IP3 receptors on the sarcoplasmic reticulum, releasing stored calcium into the cytoplasm. The rise in intracellular calcium triggers binding to calmodulin, forming the calcium-calmodulin complex, which activates MLCK. MLCK phosphorylates the regulatory myosin light chain, initiating crossbridge cycling -- the molecular mechanism of smooth muscle contraction. DAG simultaneously activates PKC, contributing additional contractile protein phosphorylation and sustaining contraction. This Gq/PLC/IP3/calcium/calmodulin/MLCK pathway is the primary mechanism of alpha1-mediated vasoconstriction.
Option A: Option A is incorrect -- Gs/cAMP/PKA signaling inhibits MLCK and promotes smooth muscle relaxation; beta2-adrenergic receptors use this mechanism for bronchodilation.
Option B: Option B is incorrect -- Gi/reduced cAMP is not the primary mechanism of alpha1-mediated contraction; alpha1 receptors are Gq-coupled.
Option D: Option D describes Rho kinase-mediated calcium sensitization, primarily G-alpha-12/13-dependent, which is a complementary but not the primary alpha1 signaling pathway.
Option E: Option E is incorrect -- phospholipase A2 and prostaglandin synthesis leading to cAMP elevation and smooth muscle relaxation is the opposite of alpha1 contractile signaling.
10. Rocuronium produces neuromuscular blockade through which mechanism and is reversed by which pharmacological approach?
A) Depolarizing blockade -- rocuronium acts as a nicotinic agonist at the NMJ; reversal is achieved by neostigmine, which prevents further succinylcholine-like depolarization
B) Competitive reversible antagonism at the nicotinic ACh receptor -- rocuronium competes with acetylcholine for binding at the two alpha subunit binding sites of the NMJ nicotinic receptor; the block is surmountable by increasing ACh concentration, achieved pharmacologically by neostigmine (AChE inhibitor); alternatively, sugammadex directly encapsulates rocuronium molecules in plasma, rapidly pulling them away from the receptor and reversing blockade by mass action
C) Non-competitive channel block -- rocuronium enters the open nicotinic channel and physically blocks ion flow; reversal requires waiting for spontaneous channel reopening as rocuronium gradually diffuses out
D) Allosteric inhibition at the delta subunit interface -- rocuronium locks the nicotinic receptor in a closed conformation without occupying the ACh binding site; reversal is achieved by competitive displacement using high-dose ACh from neostigmine-inhibited AChE
E) Irreversible covalent modification of the ACh binding site -- rocuronium alkylates the nicotinic receptor permanently; recovery requires synthesis of new receptor protein over 24-48 hours
ANSWER: B
Rationale:
Rocuronium is a non-depolarizing (competitive reversible) neuromuscular blocking agent. It competes with acetylcholine for the two alpha subunit binding sites on the muscle-type nicotinic receptor at the neuromuscular junction. Because both alpha subunit sites must be unoccupied for the channel to open normally, rocuronium at sufficient concentrations prevents ACh-mediated end-plate depolarization and blocks neuromuscular transmission. The block is competitive and surmountable -- increasing ACh concentration can overcome rocuronium occupancy. Neostigmine reversal works by inhibiting acetylcholinesterase, allowing ACh to accumulate at the NMJ and competitively displace rocuronium. Sugammadex works through a completely different mechanism -- it is a modified gamma-cyclodextrin that encapsulates rocuronium (and vecuronium) with high affinity in plasma, dramatically reducing free rocuronium concentration and drawing it away from the NMJ receptor by mass action. This provides faster and more complete reversal than neostigmine even of deep blockade.
Option A: Option A is incorrect -- rocuronium is a competitive antagonist, not a depolarizing agonist; it does not cause fasciculations.
Option C: Option C is incorrect -- non-competitive channel block is the mechanism of drugs such as memantine at NMDA receptors; rocuronium competes at orthosteric ACh sites.
Option D: Option D is incorrect -- rocuronium competes at the ACh orthosteric alpha subunit sites, not at an allosteric delta subunit site.
Option E: Option E is incorrect -- rocuronium produces reversible competitive blockade; it does not covalently modify the receptor.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.